Literature DB >> 24872518

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Vincent J Venditto1, Lindsay Wieczorek2, Sebastian Molnar2, Fernando Teque3, Gary Landucci4, Douglas S Watson1, Donald Forthal4, Victoria R Polonis5, Jay A Levy3, Francis C Szoka6.   

Abstract

Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal external region (MPER) of gp41 and also cross-react with phospholipids. In this study, we investigated if chemical modifications on the MPER adjacent to 2F5 and 4E10 epitopes using mimetics of inflammation-associated posttranslational modifications to induce 2F5- and 4E10-like bNAbs can break tolerance. We synthesized a series of chemically modified peptides spanning the MPER. The serine, threonine, and tyrosine residues in the peptides were modified with sulfate, phosphate, or nitrate moieties and presented in liposomes for rabbit immunizations. All immunizations resulted in high antisera titers directed toward both the modified and unmodified immunogens. Tyrosine modification was observed to significantly suppress antiepitope responses. Sera with strong anti-gp140 titers were purified by affinity chromatography toward the MPER peptide and found to possess a higher affinity toward the MPER than did the bNAbs 2F5 and 4E10. Modest neutralization was observed in the H9 neutralization assay, but neutralization was not observed in the TZM-bl cell or peripheral blood mononuclear cell (PBMC) neutralization assay platforms. Although neutralizing antibodies were not induced by this approach, we conclude that chemical modifications can increase the immune responses to poorly immunogenic antigens, suggesting that chemical modification in an appropriate immunization protocol should be explored further as an HIV-1 vaccine strategy.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872518      PMCID: PMC4135905          DOI: 10.1128/CVI.00320-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.

Authors:  Vincent J Venditto; Douglas S Watson; Michael Motion; David Montefiori; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

2.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

3.  Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.

Authors:  Douglas S Watson; Virginia M Platt; Limin Cao; Vincent J Venditto; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

4.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

5.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

6.  Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors.

Authors:  S Munir Alam; S Moses Dennison; Baptiste Aussedat; Yusuf Vohra; Peter K Park; Alberto Fernández-Tejada; Shelley Stewart; Frederick H Jaeger; Kara Anasti; Julie H Blinn; Thomas B Kepler; Mattia Bonsignori; Hua-Xin Liao; Joseph G Sodroski; Samuel J Danishefsky; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

7.  Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.

Authors:  Jia Chen; Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Jetta Garrity; Michael S Seaman; Bing Chen
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 8.  Neutralizing antibodies to HIV-1 induced by immunization.

Authors:  Laura E McCoy; Robin A Weiss
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

9.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.

Authors:  Guang Yang; T Matt Holl; Yang Liu; Yi Li; Xiaozhi Lu; Nathan I Nicely; Thomas B Kepler; S Munir Alam; Hua-Xin Liao; Derek W Cain; Leonard Spicer; John L VandeBerg; Barton F Haynes; Garnett Kelsoe
Journal:  J Exp Med       Date:  2013-01-28       Impact factor: 14.307

10.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962

View more
  7 in total

Review 1.  Vaccine nanoparticles for protection against HIV infection.

Authors:  Marisa E Aikins; Joseph Bazzill; James J Moon
Journal:  Nanomedicine (Lond)       Date:  2017-02-21       Impact factor: 5.307

2.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

3.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

4.  An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.

Authors:  Shuai Shao; Wei-Chiao Huang; Cuiyan Lin; Mark D Hicar; Celia C LaBranche; David C Montefiori; Jonathan F Lovell
Journal:  Ann Biomed Eng       Date:  2019-12-12       Impact factor: 3.934

5.  DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.

Authors:  Lara Ajamian; Luca Melnychuk; Patrick Jean-Pierre; Gerasimos J Zaharatos
Journal:  Viruses       Date:  2018-02-27       Impact factor: 5.048

Review 6.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

7.  The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites.

Authors:  A P Rudometov; N B Rudometova; D N Shcherbakov; A A Lomzov; O N Kaplina; N S Shcherbakova; A A Ilyichev; A Yu Bakulina; L I Karpenko
Journal:  Acta Naturae       Date:  2019 Jul-Sep       Impact factor: 1.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.